Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Aquestive Therapeutics stock

Learn how to easily invest in Aquestive Therapeutics stock.

Aquestive Therapeutics Inc is a drug manufacturers-specialty & generic business based in the US. Aquestive Therapeutics shares (AQST) are listed on the NASDAQ and all prices are listed in US Dollars. Aquestive Therapeutics employs 187 staff and has a trailing 12-month revenue of around 0.00.

How to buy shares in Aquestive Therapeutics

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – AQST – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Aquestive Therapeutics stock price (NASDAQ: AQST)

Use our graph to track the performance of AQST stocks over time.

Aquestive Therapeutics shares at a glance

Information last updated 2022-01-23.
Latest market close$2.70
52-week range$2.60 - $7.00
50-day moving average $4.87
200-day moving average $4.26
Wall St. target price$15.00
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-1.70

Buy Aquestive Therapeutics shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
Name Product Asset types Option trade fee Annual fee Signup bonus
M1 Finance
Free 1-year trial of M1 Plus
when you sign up for M1 Finance
Invest in your favorite stocks or in curated portfolios with automatic rebalancing.
SoFi Invest
Stocks, ETFs, Cryptocurrency
Get one free stock worth up to $1,000
Open an account
A free way to invest in most equities.
Stocks, Bonds, Options, Mutual funds, ETFs, Cryptocurrency
$0 + $0.50/contract
$0 per month
$10 of crypto
Open an account with access to crypto
A platform built for all kinds of traders and all styles of trading
Stocks, Options, ETFs, Cryptocurrency
Free stock (chosen randomly with a value anywhere between $2.50 and $200)
Sign up using the "go to site" link
Make unlimited commission-free trades in stocks, funds, and options with Robinhood Financial.
Stash Invest
Stocks, ETFs
$1 per month
Add at least $5 to your Invest account
Stash is more than an investment app. You’ll have access to tools that can help you become a confident investor.
Stocks, ETFs, Cryptocurrency
$0 per month
Download and sign up with; approved accounts receive a free stock slice worth up to $300, selected from 9 popular stocks.
Open an account
Commission-free trading in stocks and ETFs with a social networking twist.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Aquestive Therapeutics stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Aquestive Therapeutics price performance over time

Historical closes compared with the close of $2.7 from 2022-01-26

1 week (2022-01-19) -21.74%
1 month (2021-12-27) -31.82%
3 months (2021-10-23) N/A
6 months (2021-07-27) -20.12%
1 year (2021-01-27) -51.00%
2 years (2020-01-27) -30.77%
3 years (2019-01-25) 7.92
5 years (2017-01-23) N/A

Aquestive Therapeutics financials

Revenue TTM $46.9 million
Gross profit TTM $32.9 million
Return on assets TTM -41.76%
Return on equity TTM 0%
Profit margin -132.11%
Book value $-0.99
Market capitalisation $118.5 million

TTM: trailing 12 months

Aquestive Therapeutics share dividends

We're not expecting Aquestive Therapeutics to pay a dividend over the next 12 months.

Aquestive Therapeutics share price volatility

Over the last 12 months, Aquestive Therapeutics's shares have ranged in value from as little as $2.595 up to $6.997. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aquestive Therapeutics's is 3.3349. This would suggest that Aquestive Therapeutics's shares are significantly more volatile than the average for this exchange and represent a higher risk.

Aquestive Therapeutics overview

Aquestive Therapeutics, Inc. , a pharmaceutical company, focuses on identifying, developing, and commercializing various products to address unmet medical needs in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; and Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery. The company's proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. Its proprietary pipeline of complex molecule products include AQST-108, a sublingual film formulation of epinephrine for the treatment of anaphylaxis; and AQST-305, a sublingual film formulation of octreotide for the treatment of acromegaly. Further, the company develops KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease. Aquestive Therapeutics, Inc.

Frequently asked questions

What percentage of Aquestive Therapeutics is owned by insiders or institutions?
Currently 2.801% of Aquestive Therapeutics shares are held by insiders and 37.081% by institutions.
How many people work for Aquestive Therapeutics?
Latest data suggests 187 work at Aquestive Therapeutics.
When does the fiscal year end for Aquestive Therapeutics?
Aquestive Therapeutics's fiscal year ends in December.
Where is Aquestive Therapeutics based?
Aquestive Therapeutics's address is: 30 Technology Drive, Warren, NJ, United States, 07059
What is Aquestive Therapeutics's ISIN number?
Aquestive Therapeutics's international securities identification number is: US03843E1047
What is Aquestive Therapeutics's CUSIP number?
Aquestive Therapeutics's Committee on Uniform Securities Identification Procedures number is: 03843E104

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site